BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celgene Corporation (CELG) Elects James J. Loughlin To Board Of Directors


1/8/2007 2:43:09 PM

SUMMIT, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Celgene Corporation announced the election of James J. Loughlin to the Company's Board of Directors. Mr. Loughlin is an experienced corporate director with a distinguished 40-year career with one of the world's leading professional accounting and business consulting firms where he reached the highest levels of corporate management and governance from entry level in 1964 to National Director of the Pharmaceuticals Practice, including a five-year term as member of the Board of Directors of KPMG LLP.

Mr. Loughlin served as chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. As Partner, Mr. Loughlin led multinational audits of pharmaceutical and financial services companies. Mr. Loughlin also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees.

"Celgene will benefit substantially from Jim's extensive financial and business consulting expertise," said Sol. J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene Corporation. "He is a welcomed addition to the Board and we look forward to his valuable contributions."

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

Celgene Corporation

CONTACT: Robert J. Hugin, President and Chief Operating Officer,+1-908-673-9102, or Brian P. Gill, Vice President, CorporateCommunications, +1-908-673-9530, both of Celgene Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES